Thomas Liquard - Aug 10, 2021 Form 3 Insider Report for PharmaCyte Biotech, Inc. (PMCB)

Role
Director
Signature
/s/ Thomas Liquard
Stock symbol
PMCB
Transactions as of
Aug 10, 2021
Transactions value $
$0
Form type
3
Date filed
8/20/2021, 08:36 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PMCB Common Stock 1.67K Aug 10, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PMCB Stock Option (right to buy) Aug 10, 2021 Common Stock 167 $156.00 Direct F1, F2
holding PMCB Stock Option (right to buy) Aug 10, 2021 Common Stock 167 $87.00 Direct F1, F2
holding PMCB Stock Option (right to buy) Aug 10, 2021 Common Stock 334 $80.85 Direct F1, F2
holding PMCB Stock Option (right to buy) Aug 10, 2021 Common Stock 334 $60.60 Direct F1, F2
holding PMCB Stock Option (right to buy) Aug 10, 2021 Common Stock 334 $36.00 Direct F1, F2
holding PMCB Stock Option (right to buy) Aug 10, 2021 Common Stock 334 $26.55 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of shares has been adjusted to reflect a one-for-1,500 reverse stock split of the Issuer's common stock effected on July 12, 2021 (the "Reverse Split").
F2 The exercise price has been adjusted to reflect the Reverse Split.